4.5 Article

Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 62, 期 2, 页码 745-756

出版社

IOS PRESS
DOI: 10.3233/JAD-170834

关键词

Alzheimer's disease risk; Clinical Dementia Rating sum of boxes; International Genomics of Alzheimer's Project (IGAP); polygenic risk score; progression

资金

  1. National Institutes of Health [R01-AG044546, P01-AG003991, RF1AG053303, R01-AG035083, R01-NS085419]
  2. Alzheimer Association [BAND-14-338165]
  3. NIH [P50-AG05681, P01-AG03991, P01-AG026276]
  4. Hope Center for Neurological Disorders
  5. Departments of Neurology and Psychiatry at Washington University School of Medicine
  6. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01AG024904]
  7. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  8. National Institute on Aging
  9. National Institute of Biomedical Imaging and Bioengineering
  10. AbbVie
  11. Alzheimer's Association
  12. Alzheimer's Drug Discovery Foundation
  13. Araclon Biotech
  14. BioClinica, Inc.
  15. Biogen
  16. Bristol-Myers Squibb Company
  17. CereSpir, Inc.
  18. Cogstate
  19. Eisai Inc.
  20. Elan Pharmaceuticals, Inc.
  21. Eli Lilly and Company
  22. EuroImmun
  23. F. Hoffmann-La Roche Ltd
  24. Canadian Institutes of Health Research
  25. Genentech, Inc.
  26. Fujirebio
  27. GE Healthcare
  28. IXICO Ltd.
  29. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  30. Johnson & Johnson Pharmaceutical Research & Development LLC.
  31. Lumosity
  32. Lundbeck
  33. Merck Co., Inc.
  34. Meso Scale Diagnostics, LLC.
  35. NeuroRx Research
  36. Neurotrack Technologies
  37. Novartis Pharmaceuticals Corporation
  38. Pfizer Inc.
  39. Piramal Imaging
  40. Servier
  41. Takeda Pharmaceutical Company
  42. Transition Therapeutics
  43. NATIONAL INSTITUTE ON AGING [P01AG003991, RF1AG044546, P50AG005681, P01AG026276, R01AG044546, RF1AG053303] Funding Source: NIH RePORTER
  44. NATIONAL INSTITUTE ON DRUG ABUSE [R25DA027995] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Many genetic studies for Alzheimer's disease (AD) have been focused on the identification of common genetic variants associated with AD risk and not on other aspects of the disease, such as age at onset or rate of dementia progression. There are multiple approaches to untangling the genetic architecture of these phenotypes. We hypothesized that the genetic architecture of rate of progression is different than the risk for developing AD dementia. To test this hypothesis, we used longitudinal clinical data from ADNI and the Knight-ADRC at Washington University, and we calculated PRS (polygenic risk score) based on the IGAP study to compare the genetic architecture of AD risk and dementia progression. Dementia progression was measured by the change of Clinical Dementia Rating Sum of Boxes (CDR)-SB per year. Out of the 21 loci for AD risk, no association with the rate of dementia progression was found. The PRS rate was significantly associated with the rate of dementia progression (beta = 0.146, p = 0.03). In the case of rare variants, TREM2 (beta = 0.309, p = 0.02) was also associated with the rate of dementia progression. TREM2 variant carriers showed a 23% faster rate of dementia compared with non-variant carriers. In conclusion, our results indicate that the recently identified common and rare variants for AD susceptibility have a limited impact on the rate of dementia progression in AD patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据